Hey, are you related to that guy who used to post here just after ASH telling us that BLUE would crater back to the $50s? He really knew his stuff.
Serious question... Are you mentally ill? Because if you actually put a sign on your front lawn like that, pretty sure all of your neighbors will think so.
Nice find, dc. Has the company announced that it is doing preclinical work on such things as HIV and malaria? Their website lists no such thing currently, but it does seem worthy of speculation.
CASE IN POINT: If SRPT was likely to hit 52-week lows again for the reasons you stated, no way would it have managed to stay green on a day like today.
The heavy March call volume would suggest that's bunk. And while you could make an argument that the calls are being sold as covered calls, you also have to consider that there was huge March call activity at the end of February too, while the stock was consolidating. And those calls are still in the OI. So it's unlikely that the NDA isn't going to be submitted this quarter. More likely something else is in the works.
You're going to look like a fool at this time next year. Secondly, someone is sitting on a ton of September $140 calls bought awhile back, and they haven't sold. Pay attention.
Nope. The presentation was cancelled. With the massive volume and price surge, that should tell you something.
We aren't going to revisit 52-week lows unless a) bad news is released, or b) the entire market drops hard. In technical terms, the 52-week low has more than likely been reached. I wouldn't hold out for $11s again.
If you listened to the CEO's last presentation, you'll realize these dates are, unfortunately, highly unlikely. If you consider the company's history, you'll realize it even more. Not trying to be a Debbie Downer, but creating expectations such as these all but guarantees the stock takes a bigger dump when they don't come true. It has happened time and again over the past two years. Better to expect little and be surprised than to expect too much and be disappointed yet again, IMHO.
I think your guess is correct. If you've also paid attention to the CEO at the past few conferences, you'll notice that he's shifted his tone on SCD from cautious to "We think this could be a functional cure." Hmmm...
I think a lot of people are underestimating how rapidly this stock will move if that first SCD patient is functionally cured. We're looking at $200 at least, and probably closer to $250. And that's without CAR-T being baked in. On that topic, the CEO has repeatedly stated that BLUE's drug will be best in class. I believe him.
If good b-thal data can propel the stock from the high $20s to $112 in ten months, what can a monster game changer such as SCD do for the stock? Granted, b-thal has caused some baked-in price for SCD, but your target of $150 is way too low. If the current patient on SCD therapy is functionally cured, I think we're looking at a 100% pop at a minimum. Within a year of that, who knows given the addition of CAR-T and more b-thal and SCD data. The potential gains here are massive, even at the current price.
Um, no. BLUE is not working with INO and it never will. INO is junk. BLUE, on the other hand, is the real deal. Go away, pumper.
I really hope a buyout isn't in the works, and frankly, I kind of doubt it is. I don't think the CEO has that on his mind at this point. Not until CAR-T data starts flowing in at least. I hope BLUE isn't bought out anytime soon. I'll take the longterm value over a quick gain on this one because the potential longterm gains are mind-blowing.